熱門資訊> 正文
Sagimet Biosciences任命新财务主管
2024-05-06 20:09
- Clinical-stage biopharmaceutical company Sagimet Biosciences (NASDAQ:SGMT) appointed Thierry Chauche as CFO, effective today, May 6, 2024.
- Most recently he served as Chief Financial Officer of Provention Bio, a publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including Type 1 Diabetes.
More on Sagimet Biosciences
- Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
- Sagimet stock jumps 23% in wake of Q4 report, business updates
- Sagimet Biosciences GAAP EPS of -$2.66 beats by $34.65, revenue of $2M in-line
- Historical earnings data for Sagimet Biosciences
- Financial information for Sagimet Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
